Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
The landscape of cancer treatment is continuously evolving, with kinase inhibitors playing a pivotal role in revolutionizing patient care. These molecules are designed to interfere with specific enzymes, known as kinases, that are often dysregulated in cancer cells, driving their growth and survival. Among the most studied and promising kinase inhibitors is Pelitinib, a compound that NINGBO INNO PHARMCHEM CO.,LTD. is pleased to support through its supply of research-grade materials.
Pelitinib, also recognized as EKB-569, is a prime example of an irreversible pan-ErbB tyrosine kinase inhibitor. Its development is a testament to the progress made in oncology drug discovery. By irreversibly binding to the ATP-binding site of EGFR family kinases (EGFR, ErbB-2, ErbB-4), Pelitinib effectively shuts down critical signaling pathways. This targeted action leads to the inhibition of tumor cell proliferation and promotes apoptosis, offering a more precise and less toxic approach compared to traditional chemotherapy. The ability of Pelitinib to act as a pan-ErbB inhibitor means it can target multiple receptors within this family, potentially overcoming resistance mechanisms that might arise with single-target inhibitors.
As a crucial pharmaceutical intermediate, Pelitinib is indispensable for researchers working on the front lines of cancer drug development. NINGBO INNO PHARMCHEM CO.,LTD. provides high-purity Pelitinib to facilitate vital kinase inhibitor research chemicals and to further the understanding of their therapeutic applications. The intricate process of developing new cancer treatments often begins with such compounds, allowing scientists to explore their efficacy, safety profiles, and synergistic effects with other agents. The availability of reliable intermediates is key to ensuring the reproducibility and validity of research findings.
The significance of Pelitinib extends to its potential in treating various solid tumors. Its mechanism of action, which involves disrupting the EGFR signal transduction pathway, is particularly relevant for cancers driven by mutations or amplifications in these receptors. The ongoing research into Pelitinib's potential applications continues to shed light on its therapeutic value and its place within the broader spectrum of targeted cancer therapies. Companies like NINGBO INNO PHARMCHEM CO.,LTD. are committed to providing the scientific community with the tools necessary to advance this critical research.
In summary, the field of kinase inhibitors, exemplified by Pelitinib, is at the forefront of modern cancer treatment. By understanding how these molecules work and by supporting their research and development through the provision of high-quality pharmaceutical intermediates, NINGBO INNO PHARMCHEM CO.,LTD. contributes to the ongoing effort to combat cancer and improve patient lives.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
